The stock price of Syntekabio is on the rise. As interest in medical artificial intelligence (AI) grows, Syntekabio, an AI drug development company, appears to be gaining attention. On the same day, CrowdWorks surged to the upper price limit, improving investor sentiment toward AI-related stocks. Polaris Office and Vuno also experienced sharp increases. Lunit highlighted the growth potential of the AI industry by announcing plans to achieve KRW 10 trillion in sales and KRW 5 trillion in operating profit by 2033, based on new businesses and mergers and acquisitions.
At 1:22 PM on the 31st, Syntekabio was trading at KRW 16,600, up 7.3% from the previous day.
Leading medical AI stocks such as Lunit and Vuno have risen approximately 490% and 800%, respectively, since the beginning of this year. Syntekabio, which is developing new drugs using AI, has increased by 95%.
Earlier, on the 28th, Syntekabio announced that it had signed a strategic business agreement (MOU) with Polaris Quantum Biotech in the United States. They agreed to provide AI drug candidate discovery services combining AI and quantum computing.
Using its self-developed AI platform for drug candidate discovery, Syntekabio will begin searching for initial hits. Among numerous initial hits derived from each platform, the service will provide clients with drug candidates that have high development potential.
Polaris QB is a quantum computing-based drug development company located in North Carolina, USA. It owns QuADD, a drug candidate generation platform based on a quantum annealer. It is characterized by using a massive library of 10 to the 30th power.
Syntekabio is preparing genome big data and AI drug platform services covering the entire drug development cycle based on its own cloud supercomputing infrastructure. This includes services from hit discovery to preclinical stages (DDC) and genome biomarker discovery and detection services necessary for the entire drug development process.
Shahar Keinan, founder and CEO of Polaris QB, said, "QuADD is a quantum mechanics-based platform that can provide services in overseas markets and is a commercialized product in the drug design sector," and added, "By providing drug development services together with Syntekabio’s cloud supercomputing infrastructure and genome-based AI platform, we expect to quickly and efficiently identify lead compounds."
Jung Jong-sun, CEO of Syntekabio, expressed expectations that "this will greatly help expand overseas business opportunities."
Quantum technology is regarded as a game changer that will bring disruptive innovation in economic, security, and industrial aspects. In June, the government announced the ‘Korea Quantum Science and Technology Strategy,’ pledging full support for nurturing related personnel and industries to raise the technology level to 85% of leading countries by developing a 1,000-qubit quantum computer by the early 2030s.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
